ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
16.73
-0.86 (-4.89%)
At close: Jul 18, 2025, 4:00 PM
16.53
-0.20 (-1.19%)
After-hours: Jul 18, 2025, 7:55 PM EDT

ADMA Biologics Stock Forecast

Stock Price Forecast

The 3 analysts that cover ADMA Biologics stock have a consensus rating of "Strong Buy" and an average price target of $27.67, which forecasts a 65.39% increase in the stock price over the next year. The lowest target is $25 and the highest is $32.

Price Target: $27.67 (+65.39%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$25$27.67$26$32
Change+49.43%+65.39%+55.41%+91.27%
* Price targets were last updated on May 8, 2025.

Analyst Ratings

The average analyst rating for ADMA Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingFeb '25Mar '25Apr '25May '25Jun '25Jul '25
Strong Buy333332
Buy111111
Hold000000
Sell000000
Strong Sell000000
Total444443

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Raymond James
Raymond James
Strong Buy
Maintains
$25$32
Strong BuyMaintains$25$32+91.27%May 8, 2025
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterates
$25
BuyReiterates$25+49.43%Mar 4, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$18$26
Strong BuyMaintains$18$26+55.41%Nov 8, 2024
Raymond James
Raymond James
Strong Buy
Maintains
$18$25
Strong BuyMaintains$18$25+49.43%Nov 8, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$18
Strong BuyReiterates$18+7.59%Oct 14, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
517.82M
from 426.45M
Increased by 21.42%
Revenue Next Year
653.99M
from 517.82M
Increased by 26.30%
EPS This Year
0.62
from 0.81
Decreased by -23.60%
EPS Next Year
0.95
from 0.62
Increased by 53.84%
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
42.22M80.94M154.08M258.22M426.45M517.82M653.99M843.85M
Revenue Growth
43.85%91.72%90.36%67.59%65.16%21.42%26.30%29.03%
EPS
-0.88-0.51-0.33-0.130.810.620.951.31
EPS Growth
------23.60%53.84%37.14%
Forward PE
-----27.0417.5712.81
No. Analysts
-----666
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue202520262027
High537.6M683.6M909.5M
Avg517.8M654.0M843.9M
Low495.1M618.7M777.8M

Revenue Growth

Revenue Growth202520262027
High
26.1%
32.0%
39.1%
Avg
21.4%
26.3%
29.0%
Low
16.1%
19.5%
18.9%

EPS Forecast

EPS20252026202720282029
High0.641.011.41
Avg0.620.951.31
Low0.590.871.18

EPS Growth

EPS Growth20252026202720282029
High
-20.9%
62.9%
47.8%
Avg
-23.6%
53.8%
37.1%
Low
-27.4%
40.9%
23.5%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.